We recently published a list of 10 Best Blue Chip Stocks to Buy for 2025. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best blue chip stocks to buy for 2025.
Both conservative and risk-tolerant investors favor blue chip stocks due to their solid business models, impressive track records, and attractive risk-reward profiles. These stocks are backed by companies with strong brand names and reputations that generate dependable earnings and consistent dividends, which provide stability and passive income during turbulent market conditions.
In recent years, Wall Street has become reliant on the best blue chip stocks. While the S&P 500 was up by about 24% in 2024, most of the gains were driven by gains in seven of the biggest blue chip stocks. The “Magnificent 7” stocks, which include seven of the biggest companies by market cap, accounted for a 13.7% point gain in the S&P 500. Therefore, investors who focused on these stocks ended up generating significant gains.
READ ALSO: Billionaire Israel Englander’s Top 10 Stock Picks Heading Into 2025 and 15 Stocks Targeted By Activist Hedge Funds.
The trend is not expected to change in 2025. Blue chip companies should be the biggest beneficiary as the Federal Reserve cuts interest rates and the new administration under Donald Trump pushes for fewer regulations. The easing of regulatory pressure that has taken a significant toll on tech giants should be a boon to see blue chip stocks edge even higher. David Miller, co-founder at Catalyst Funds, expects blue chip stocks to continue leading the way in 2025.
“The Mag 7 stocks are generating significant growth in terms of revenue and earnings power,” he said earlier this month. “These companies are massive monopoly businesses with strong fundamental tail winds. I have no reason to believe that the Mag 7 names won’t continue to dominate the S&P in 2025.”
Valuations among the blue-chip stocks have gotten out of hand after two years of blockbuster gains amid the artificial intelligence frenzy. Blue chip companies boast significant profits and a competitive edge to back their valuations up, however.
“The Magnificent Seven are not pie-in-the-sky companies: They’re generating “tremendous” revenue for investors”, said Fitzgerald, principal and founding member of Moisand Fitzgerald Tamayo. “How much more gain can be made is the question,” he added.
Therefore, any well-diversified investment portfolio should include some of the best blue chip stocks. It’s the only way investors can take advantage of the market rally that’s driven by various factors, including the artificial intelligence frenzy, robust economic growth and friendly monetary policy.
Our Methodology
To make our list of the 10 best blue chip stocks to buy for 2025, we analyzed the market, focusing on large market cap companies (more than $100 billion) with well-established, financially sound businesses. We then examined their performance over the past year, focusing on the underlying fundamentals that make them stand out. Finally, we ranked these companies in ascending order based on their 12-month return in 2024.
At Insider Monkey, we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
An array of pharmaceutical pills with the company’s logo on the bottle.
Eli Lilly and Company (NYSE:LLY)
Market Cap as of January 8: $707.96 Billion
Past Year Gain (2024): 26%
Number of Hedge Fund Holders: 106
Eli Lilly and Company (NYSE:LLY) is a company that discovers, develops, and markets human pharmaceuticals worldwide. It is one of the best blue chip stocks for 2025 amid growing demand for weight loss and diabetes treatment options. The company boasts of a robust pipeline of glucagon-like peptide-1 (GLP-1) receptor agonist drugs.
Eli Lilly and Company’s (NYSE:LLY) Mounjaro and Zepbound drugs are proving effective in helping patients lose weight, attracting billions of dollars in revenues. Mounjaro revenue more than doubled to $3.11 billion in Q3 as Zepbound added an additional $1.26 billion. Mounjaro stands out in helping patients with type 2 diabetes improve blood sugar, while Zepbound is effective in weight loss in obese adults.
Eli Lily’s long-term outlook remains solid, with management having projected a 50% year-over-year revenue increase for Q4. Strong demand for drugs is the catalyst behind the company’s increasing production capacity as it also looks to diversify its revenue streams with expansion into new international markets. Eli Lilly and Company (NYSE:LLY) is also in the process of investing $20 billion to build, upgrade and acquire manufacturing facilities as it looks to fulfill the ever-increasing drug orders.
Overall, LLY ranks 8th on our list of best blue chip stocks to buy for 2025. While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that some deeply undervalued AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for a deeply undervalued AI stock that is more promising than LLY but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock
Disclosure: None. This article is originally published at Insider Monkey.